News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CICC Raises INNOVENT BIO (01801.HK) TP to $69 as Colorectal Cancer Drug Data Beats Forecasts
INNOVENT BIO (01801.HK) presented multiple datat the 2025 ASCO Annual Meeting, with particular attention on the PD-1/IL-2α-bias bispecific antibody fusion protein IBI363, CICC...
Reset
Send
The window will close in 5 seconds
<Research>CICC Raises INNOVENT BIO (01801.HK) TP to $69 as Colorectal Cancer Drug Data Beats Forecasts
Close
Recommend
4
Positive
5
Negative
1
 
SHORT SELL
 
STOCK INFO

INNOVENT BIO (01801.HK)  +0.650 (+1.092%)    Short selling $140.50M; Ratio 29.483%   presented multiple datat the 2025 ASCO Annual Meeting, with particular attention on the PD-1/IL-2α-bias bispecific antibody fusion protein IBI363, CICC published a research report saying.

The broker believed that the newly disclosed data for colorectal cancer patients exceeded expectations, and suggested that IBI363 has the potential to become a blockbuster in this field. Furthermore, IBI363 continued to demonstrate leading competitiveness in IO-treated lung cancer.

CICC maintained its 2025/ 2026 net profit forecasts for INNOVENT BIO at RMB472 million/ RMB1.3 billion, and kept rating at Outperform. Considering the higher-than-expected colorectal cancer data for IBI363, the broker raised its target price by 4.5% to $69.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-28 12:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.